Ocugen Announces Data And Safety Monitoring Board Has Recommended To Proceed With Dosing Subsequent GA Subjects With Low Dose Of OCU410 In Dose-Expansion Phase And Concurrently Initiate Phase 2 Dosing
Ocugen Announces Data And Safety Monitoring Board Has Recommended To Proceed With Dosing Subsequent GA Subjects With Low Dose Of OCU410 In Dose-Expansion Phase And Concurrently Initiate Phase 2 Dosing
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.